Basel-based Allegria Therapeutics raised $3.5 million seed round

Basel-based Allegria Therapeutics raised $3.5 million seed round

Alegria treatmentBased in Basel, Switzerland, has secured $3.5 million in seed financing led by Forty51 Ventures to advance its innovative treatments for mast cell-mediated diseases.

Allegria Therapeutics, founded in 2023 by Forty51 Ventures, is dedicated to revolutionizing the treatment of allergic and mast cell-mediated inflammatory diseases.

Company co-founder Maria van Dongen, Ph.D., has been named Chief Executive Officer. Dr. van Dongen brings extensive experience from her previous roles in the pharmaceutical industry, including work on RNA processing and peptide-based therapeutic discovery.

Allegria Therapeutics focuses on developing treatments for allergic and inflammatory diseases by targeting mast cells, which play a key role in these conditions. Despite the significant impact these diseases have on patients' lives and the limited treatment options available, Allegria aims to provide more effective solutions through its proprietary treatment methods.

The company collaborates with leading experts in mast cell biology and drug discovery, such as Prof. Markus Maurer from the Berlin charity and Dr. Philip Starkel from the Medical University of Vienna.

Forty51 Ventures has been instrumental in supporting Allegria as an early-stage investor and operational partner. Allegria was founded in Basel, a leading center for biotech and pharmaceutical innovation.

Forty51 Ventures specializes in building biotech companies and leads early financing rounds for its portfolio, which includes academia, pharmaceuticals, and biotech spinouts.

About the Author

Leave a Reply